Blueprint Medicines Corp (NASDAQ: BPMC) has reported a loss for its third fiscal quarter (ending September 30) of $-0.89 versus a loss $-2.20 for the same period a year ago — a decline of -60%. E.P.S. were $-2.09 for the latest four quarters through September 30 versus $-9.20 for the same period a year ago — a decline of -77%.
Recent Price Action
On 10/30/24, Blueprint Medicines Corp (NASDAQ: BPMC) stock enjoyed a very large increase of 7.0%, closing at $89.24. Moreover, this advance was accompanied by exceptionally high trading volume at 316% of normal. The stock has performed in line with the market over the last nine months and has risen 3.2% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, BPMC is expected to be a modest Value Builder.
Blueprint Medicines has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects complementary signals from PTR’s two proprietary measures of a stock’s attractiveness. Blueprint Medicines has a slightly negative Power Rating of 36 and a very low Appreciation Score of 1, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment